Results 201 to 210 of about 32,846 (250)

Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems. [PDF]

Pharmaceuticals (Basel)
Shokr H, Mekkawy M, Hindi A.
europepmc   +1 more source

GLP‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2806-2814, April 2026.
Abstract Aims To evaluate the cardiovascular efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations.
Masashi Hasebe, Chen‐Yang Su, Hisashi Kamido, Daisuke Yabe, Satoshi Yoshiji   +4 more
wiley   +1 more source

Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists. [PDF]

Front Cardiovasc Med
Liu L, Lu J.
europepmc   +1 more source

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2835-2848, April 2026.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2953-2961, April 2026.
Abstract Objective People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having ...
Nikolaos Fountoulakis, Panagiotis Pavlou, Dimitra Stathi, Aicha Goubar, Antonella Corcillo, Maria Flaquer, Salma Ayis, Luigi Gnudi, Janaka Karalliedde   +8 more
wiley   +1 more source

Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program. [PDF]

Front Psychiatry
Abegaz TM, Ahmed M, Bhagavathula AS, Frietze G.   +3 more
europepmc   +1 more source

Real‐world persistence and dose titration of GLP‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3386-3395, April 2026.
Abstract Aims Real‐world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP‐1 receptor agonist (GLP‐1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease (CVD) history, and sex assigned at birth.
Franziska S. Ulrich, Nicola Napoli, Morten Frost Nielsen, Andrea M. Burden   +3 more
wiley   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Journal of Internal Medicine, Volume 299, Issue 4, Page 444-466, April 2026.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg. [PDF]

Diabetes Obes Metab
Kuckuck S, van Gerwen N, Oosterman JE, Savas M, Kavousi M, Penninx BWJH, Boon MR, van Rossum EFC.   +7 more
europepmc   +1 more source

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Intermittent hypoxia (IH)‐mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking.
Cliona O'Donnell, Ailbhe King, Guillaume Vial, Emily O'Neill, Shane Crilly, Jonathan D. Dodd, David J. Murphy, Elise Belaidi, Jean‐Louis Pepin, Claire Arnaud, Donal O'Shea, Silke Ryan   +11 more
wiley   +1 more source